Atty. Docket No. P292/15

Application No. 10/565,997

ITW

## N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ryozo NAGAI et al.

Confirmation No.: 9551

Appln. No.

: 10/565,997

Group Art Unit: 1653

Filed

: January 27, 2006

Examiner: Not Yet Assigned

For

: RNA CAPABLE OF SUPPRESSING EXPRESSION OF KLF5 GENE

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop
Randolph Building
401 Dulany Street
Alexandria VA 22314

Sir:

Further to the Information Disclosure Statement filed August 14, 2006, and in accordance with the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants hereby call to the Office's attention the following information, which includes documents cited in a Supplementary European Search Report dated September 5, 2007, issued in connection with corresponding European Application No. EP 04 77 1250:

NANDAN et al., "Kruppel-Like Factor 5 (KLF5) Mediates HA-RAS-Induced Cell Transformation," Digestive Disease Week Abstracts and Itinerary Planner, Vol. 2003, Abstract No. 446 (2003);

MIYAGISHI et al., "U6 promoter-driven siRNAs with four uridine 3" overhangs efficiently suppress targeted gene expression in mammalian cells," Nature Biotechnology, Vol. 20, No. 5, pages 497-500 (2002); and

NANDAN et al., "Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras," Oncogene, Vol. 23, No. 19, pages 3404-3413 (2004).

Application No. 10/565,997

Atty. Docket No. P29215

Copies of the above-listed documents and the Supplementary Search Report for European

Application No. 04 77 1250 are enclosed together with a completed copy of the PTO-1449 Form

listing these documents. Accordingly, the Examiner is requested to consider these documents and

to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form

with the next official communication.

Applicants note that while this Supplemental Information Disclosure Statement is being

filed more than three months from the filing date, Applicants have not received an action on the

merits from the U.S. Patent and Trademark Office. Accordingly, consideration of the enclosed

documents are required under 37 C.F.R. 1.97(b)(3).

However, if an action on the merits has been mailed prior to the filing date of this

Supplemental Information Disclosure Statement, Applicants hereby authorize the charging of

any required fees necessary for consideration of the documents cited herein to Deposit Account

No. 19-0089.

If there should be any questions, the Examiner is invited to contact the undersigned at the

telephone number listed below.

Respectfully submitted, Ryozo NAGAI et al.

Stan Myn Angre Bruce H. Bernstein 42,970

Reg. No. 29,027

December 4, 2007 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191